PMID: 9187898Jan 1, 1997Paper

Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma

European Urology
S KregeH Rübben

Abstract

Though para-aortal and ipsilateral iliacal radiation is the established adjuvant treatment for clinical stage I seminoma, promising results have been reported on adjuvant single-agent carboplatin therapy. We treated 43 patients with clinical stage I seminoma according to this option. They received 2 courses of single-agent carboplatin (400 mg/m2) at an intervall of 3 weeks. Therapy could be performed on an outpatient basis within 2 h. Therapy was well tolerated. Apart from minor gastrointestinal disorders and mild myelosuppression, no adverse reactions were observed. The median follow-up is 28 months. Up to now no recurrences have been noted. If the recurrence rate remains as low as after adjuvant radiotherapy, which should be proved in a phase III study, single-agent carboplatin therapy will be an alternative adjuvant approach for clinical stage I seminoma.

Citations

Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunar K ZagarsSara S Strom
Jul 22, 2010·Expert Review of Anticancer Therapy·Jorge Aparicio, Roberto Díaz
May 16, 2002·International Journal of Urology : Official Journal of the Japanese Urological Association·Yoshiyuki KakehiOsamu Ogawa
Dec 22, 1999·International Journal of Cancer. Journal International Du Cancer·M BambergM Flink
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W J ReiterC Kratzik
Apr 18, 2007·Cancer·Jarad M MartinPadraig Warde
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald de Wit, Karim Fizazi
Jun 11, 2010·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Emma J AlexanderAlan Horwich
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy GilliganPhilip W Kantoff
Mar 29, 2011·BJU International·Hannes SteinerFlorian Zangerl
Sep 18, 2007·Der Urologe. Ausg. A·S Langenkamp, P Albers
Sep 29, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Ramón Diz-RodríguezAna Moreno Posadas
Dec 24, 2005·Oncology·F ChristophM Schrader
May 21, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Julia SkliarenkoPadraig Warde
Dec 3, 2015·Expert Opinion on Pharmacotherapy·Christoph OingCarsten Bokemeyer
Jul 20, 2002·International Journal of Radiation Oncology, Biology, Physics·Luca IncrocciA Koos Slob
Oct 29, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S KregeUNKNOWN German Testicular Cancer Study Group (GTCSG)
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollUNKNOWN European Germ Cell Cancer Consensus Group
Aug 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F HoneckerA Horwich
Dec 19, 2003·The Urologic Clinics of North America·Manish I PatelJoel Sheinfeld
Sep 5, 1998·The Urologic Clinics of North America·C N Sternberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Absence Epilepsy

Absence epilepsy is a common seizure disorder in children which can produce chronic psychosocial sequelae. Discover the latest research on absence epilepsies here.